Oscar Health (OSCR) traded higher Monday, extending a recent stretch of positive sentiment that has been driven less by a single headline and more by a confidence-building mix of (1) management’s 2026 financial framework and (2) a notable insider purchase that investors often read as a signal of conviction. The stock’s move comes with the next key catalyst approaching: the company’s next quarterly update, which market calendars broadly peg for early May.

A major attention-grabber for the tape has been CEO Mark Bertolini’s large open-market purchase: a Form 4 filing shows he bought 1,000,000 shares at $11.92 on April 6, 2026 (about $11.92 million). With OSCR now trading above that level, the transaction is being treated as a high-signal vote of confidence in the turnaround narrative and the company’s 2026 execution path.

Oscar’s latest full-year guidance framework has centered investor debate on whether the company can translate scale and operating discipline into durable profitability in 2026, including an earnings-from-operations range of $250 million to $450 million. Near-term, attention shifts to the next earnings event, with market schedules indicating Oscar’s Q1 2026 report is expected May 6, 2026—setting up a potential volatility window as investors look for early-year proof points on margins, medical cost trends, and enrollment trajectory.